This study demonstrates that FGFR signaling is a key mechanism for cells to bypass EGFR dependence and indicates the potential efficacy of co-targeting EGFR and FGFR in patients with EGFR mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.